Asandeutertinib vs Rezivertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Asandeutertinib

Marketed by TYK Medicines, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05146219 · Phase 2 · completed

The study treated 29 participants in a single arm without randomization, blinding, or a control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2027 · NCT06672068 (registry estimate)

Reported efficacy

Intracranial Overall Response Rate (iORR) (13 months.); Extracranial Overall Response Rate (eORR) (13 months.): Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months (not_applicable)

Result source: NCT05146219

Rezivertinib

Marketed by Beta Pharma, Inc.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Reliable signal

NCT03866499 · Phase 3 · status unknown

This trial randomized 369 patients to BPI-7711 or active-controlled gefitinib with full blinding of participants, care providers, investigators, and outcome assessors, testing a hard clinical endpoint (progression-free survival) that is standard for regulatory approval in NSCLC. The primary comparison was statistically significant and favored BPI-7711, with a nearly doubled median PFS and a strong hazard ratio, supporting confidence in the result.

Next expected readout: December 2030 · NCT06955325 (registry estimate)

Reported efficacy

Progression-free survival (up to approximately 16 months): REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 (met)

Result source: NCT03866499

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAsandeutertinibRezivertinib
PFS, median—Trial running · NCT05382728—Trial running · NCT06955325
OS, median—Trial running · NCT05382728—Trial running · NCT06955325
ORR—Trial running · NCT05382728—Trial running · NCT06955325
Duration of response, median—Trial running · NCT05382728—Trial running · NCT06955325

PFS, median

Asandeutertinib
—Trial running · NCT05382728
Rezivertinib
—Trial running · NCT06955325

OS, median

Asandeutertinib
—Trial running · NCT05382728
Rezivertinib
—Trial running · NCT06955325

ORR

Asandeutertinib
—Trial running · NCT05382728
Rezivertinib
—Trial running · NCT06955325

Duration of response, median

Asandeutertinib
—Trial running · NCT05382728
Rezivertinib
—Trial running · NCT06955325
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Asandeutertinib
Confirmed investigator-assessed intracranial ORR 93.1% (95% CI: 77.2%-99.2%) in 29 patients at 160 mg once daily; median PFS 13.5 months NCT05146219 · Phase 2 · design grade: weak · publication or press release
Rezivertinib
REZOR (NCT03866499), primary endpoint median PFS: rezivertinib (BPI-7711) 19.3 months vs gefitinib 9.6 months; HR 0.48 (95% CI 0.36-0.63); p<0.0001 NCT03866499 · Phase 3 · design grade: strong · publication or press release
ORR by blinded independent central review 64.6% (95% CI 58.0%-70.8%) NCT03812809 · Phase 2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asandeutertinib's landscape · Rezivertinib's landscape